Fisher Asset Management LLC Purchases 446,845 Shares of Biogen Inc. $BIIB

Fisher Asset Management LLC grew its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 132.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 784,863 shares of the biotechnology company’s stock after buying an additional 446,845 shares during the period. Fisher Asset Management LLC owned 0.53% of Biogen worth $177,285,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Probity Advisors Inc. lifted its stake in shares of Biogen by 3.6% during the third quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 41 shares during the period. Forum Financial Management LP increased its position in Biogen by 2.4% in the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 46 shares during the period. Integrated Advisors Network LLC increased its position in Biogen by 3.5% in the third quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock worth $317,000 after purchasing an additional 48 shares during the period. Wedbush Securities Inc. raised its holdings in Biogen by 5.1% during the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 56 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its holdings in Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after purchasing an additional 57 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BIIB. UBS Group raised their target price on shares of Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Truist Financial reissued a “buy” rating and set a $260.00 price target (up from $235.00) on shares of Biogen in a research note on Thursday, October 29th. Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. Oppenheimer restated an “outperform” rating and issued a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada raised their price objective on shares of Biogen from $256.00 to $272.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and an average price target of $254.41.

Check Out Our Latest Stock Analysis on Biogen

Biogen Stock Performance

NASDAQ:BIIB opened at $253.40 on Monday. Biogen Inc. has a 1-year low of $160.36 and a 1-year high of $261.00. The business’s 50-day moving average price is $233.35 and its two-hundred day moving average price is $205.04. The company has a current ratio of 1.95, a quick ratio of 1.37 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $37.46 billion, a price-to-earnings ratio of 108.29, a PEG ratio of 2.87 and a beta of 0.10.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business earned $4.81 earnings per share. On average, equities analysts expect that Biogen Inc. will post 12.46 earnings per share for the current year.

Biogen Profile

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

Read More

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.